{
    "2021-05-28": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Is Novo Nordisk A/S (NVO) A Smart Long-Term Buy?",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "long-term buy",
                        "smart"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "semaglutide",
                        "type 2 diabetes",
                        "US regulatory approval"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}